Mindstrong Health, a digital health startup transforming the diagnosis and treatment of neuropsychiatric disorders, has entered into a partnership with Takeda Pharmaceutical Company Limited to explore the development of digital biomarkers for selected mental health conditions, in particular schizophrenia and treatment-resistant depression.In this decade, neuropsychiatric disorders represent the largest source of medical disability for people under age 50. The costs are among the highest of all
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
